- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02349412
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There will be about 400 patients enrolled in this intervention study and there will be about 300 family caregivers enrolled as well. This study will consist of two study groups as previously described. The effects of the early involvement of the palliative care team will be compared to the usual approach of receiving care mostly from the cancer treatment team. The stratification factors include tumor type (lung vs. esophageal/gastric vs. hepatic/biliary/pancreatic) and family care giver participation (yes vs. no). Patients will be on this study for as long as they receive care. Institutions must have an outpatient palliative care clinic that meets the study site requirements as defined in the protocol. The outpatient clinic leadership must include a physician and/or advanced practice nurses board certified in palliative care. The primary and secondary endpoints are described below.
Primary Endpoint:
To determine the efficacy of early integrated palliative care on patient reported quality of life at 12 weeks using the FACT in patients with newly diagnosed incurable lung or non-colorectal gastrointestinal cancer
Secondary Endpoints:
- To determine the efficacy of early integrated palliative care on other patient reported outcomes in patients with newly diagnosed incurable lung or non-colorectal gastrointestinal cancer, by assessing the endpoints defined in the protocol
- To determine the efficacy of early integrated palliative care on family caregiver reported outcomes in those newly diagnosed incurable lung or non-colorectal gastrointestinal cancer, by assessing the endpoints defined in the protocol
- To assess the impact of early integrated palliative care on the quality of end-of-life care and resource utilization in patients with newly diagnosed incurable lung or non-colorectal gastrointestinal cancer by assessing the endpoints defined in the protocol
- To determine concordance between patient and family caregiver report of prognosis/ curability
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- UC San Diego Moores Cancer Center
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- Queen's Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Comprehensive Cancer Center
-
Evanston, Illinois, United States, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Glenview, Illinois, United States, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, United States, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital Cancer Center
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Mercy Health Saint Mary's
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55415
- Hennepin County Medical Center
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
Saint Louis Park, Minnesota, United States, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, United States, 55101
- Regions Hospital
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth Hitchcock Medical Center
-
-
New York
-
New Hyde Park, New York, United States, 11040
- North Shore-LIJ Health System/Center for Advanced Medicine
-
New York, New York, United States, 10032
- Columbia University/Herbert Irving Cancer Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
North Dakota
-
Grand Forks, North Dakota, United States, 58201
- Altru Cancer Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Health Sciences Center
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University/Massey Cancer Center
-
-
Wisconsin
-
La Crosse, Wisconsin, United States, 54601
- Gundersen Lutheran Medical Center
-
Marshfield, Wisconsin, United States, 54449
- Marshfield Clinic
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert and The Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Study Patient Participant Eligibility Requirements:
- Documentation of Disease: Confirmed advanced lung cancer (NSCLC, small cell lung cancer, or mesothelioma) or non-colorectal GI cancer (esophageal, gastric, hepatic, biliary, or pancreatic) not being treated with curative intent.
- Informed of diagnosis of incurable disease within the previous 8 weeks.
- Age ≥ 18 years
- ECOG Performance Status 0-2
- Ability to read and respond to questions in English or able to complete questions with minimal assistance required from an interpreter or family member.
- Planning to receive all medical care for cancer at the enrolling institution.
- Participants must be under the care of an oncologist, but their current plan may or may not include chemotherapy or other forms of tumor-directed therapies.
Study Family Caregiver Participant Eligibility Requirements:
- Relative or friend who is identified by the patient participant who plans to regularly accompany the patient to the majority of their clinic visits.
- Family caregiver must live with the patient or have in-person contact with him or her at least twice per week.
- Ability to read and respond to questions in English or able to complete questions with minimal assistance required from an interpreter or family member.
- Age ≥ 18 years
Note: An eligible patient may participate in this trial without an eligible family caregiver being registered.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
Patients receive early palliative care and standard oncology care.
Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24.
Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
|
|
Experimental: Arm 2
Patients receive standard oncology care.
Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24.
Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
Palliative care visit only upon request from attending oncologist(s) or patient/family.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G)
Time Frame: Up to 12 weeks
|
Quality of Life (QOL) was measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL.
Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12.
Higher scores on FACT-G indicate better QOL.
|
Up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: Up to 3 years
|
Up to 3 years
|
|
Change in Quality of Life (QOL) From Baseline to Week 24 Per the Functional Assessment of Cancer Therapy-General (FACT-G)
Time Frame: Up to 24 weeks
|
Quality of Life (QOL) was measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL.
Change from baseline to week-24 was calculated by subtracting the baseline scores from the scores at week-24.
Higher scores on FACT-G indicate better QOL.
|
Up to 24 weeks
|
Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Depression
Time Frame: Up to 12 weeks
|
Quality of Life (QOL) was measured using the Hospital Anxiety and Depression Scale (HADS) - Depression on a 0-21 scale, with lower scores corresponding to lower depression and higher scores corresponding to higher depression.
Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12.
Lower scores on the HADS-Depression indicate less depression symptoms.
|
Up to 12 weeks
|
Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Anxiety
Time Frame: Up to 12 weeks
|
Quality of Life (QOL) was measured using the Hospital Anxiety and Depression Scale (HADS) - Anxiety on a 0-21 scale, with lower scores corresponding to lower anxiety and higher scores corresponding to higher anxiety.
Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12.
Lower scores on the HADS-Anxiety indicate less anxiety symptoms.
|
Up to 12 weeks
|
Prognostic Understanding at Week-12 as Measured by "Have You and Your Oncologist Discussed Any Particular Wishes About the Care You Would Want to Receive if You Were Dying?" Question on the Prognosis and Treatment Perceptions Questionnaire
Time Frame: Up to 12 weeks
|
Prognostic Understanding at Week-12 as measured by Prognosis and Treatment Perceptions Questionnaire: "Have you and your oncologist discussed any particular wishes about the care you would want to receive if you were dying?" responses at Week-12 are reported below.
|
Up to 12 weeks
|
Change in QOL on the SF-36 Over Time
Time Frame: Up to 3 years
|
Up to 3 years
|
|
Rate of Referral, Enrollment and Length of Stay on Hospice
Time Frame: Up to 3 years
|
Up to 3 years
|
|
Location of Death
Time Frame: Up to 3 years
|
Up to 3 years
|
|
Number of Hospital and Intensive Care Unit (ICU) Admissions and Days
Time Frame: Up to 3 years
|
Up to 3 years
|
|
Chemotherapy and Radiation Administration
Time Frame: Up to 3 years
|
Up to 3 years
|
|
Concordance Between Patient and Family Caregiver Report of Prognosis/Curability
Time Frame: Up to 3 years
|
Up to 3 years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Jennifer Temel, MD, Massachusetts General Hospital
Publications and helpful links
General Publications
- Temel JS, Sloan J, Zemla T, Greer JA, Jackson VA, El-Jawahri A, Kamdar M, Kamal A, Blinderman CD, Strand J, Zylla D, Daugherty C, Furqan M, Obel J, Razaq M, Roeland EJ, Loprinzi C. Multisite, Randomized Trial of Early Integrated Palliative and Oncology Care in Patients with Advanced Lung and Gastrointestinal Cancer: Alliance A221303. J Palliat Med. 2020 Jul;23(7):922-929. doi: 10.1089/jpm.2019.0377. Epub 2020 Feb 7.
- Jacobs JM, Shaffer KM, Nipp RD, Fishbein JN, MacDonald J, El-Jawahri A, Pirl WF, Jackson VA, Park ER, Temel JS, Greer JA. Distress is Interdependent in Patients and Caregivers with Newly Diagnosed Incurable Cancers. Ann Behav Med. 2017 Aug;51(4):519-531. doi: 10.1007/s12160-017-9875-3.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Digestive System Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Biliary Tract Diseases
- Adenoma
- Bile Duct Diseases
- Neoplasms, Mesothelial
- Pleural Neoplasms
- Biliary Tract Neoplasms
- Lung Neoplasms
- Anxiety Disorders
- Small Cell Lung Carcinoma
- Mesothelioma
- Mesothelioma, Malignant
- Bile Duct Neoplasms
Other Study ID Numbers
- A221303
- UG1CA189823 (U.S. NIH Grant/Contract)
- U10CA037447 (U.S. NIH Grant/Contract)
- NCI-2014-01943 (Registry Identifier: NCI Clinical Trial Reporting Program Office)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Lawson Health Research InstituteTerminated
Clinical Trials on Early palliative care
-
Istituto Scientifico Romagnolo per lo Studio e...Completed
-
Inna Chen, MDOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsRecruitingPancreatic CancerDenmark
-
Central Hospital, Nancy, FranceUnknown
-
Pippa HawleyCompleted
-
McMaster UniversitySt. Joseph's Healthcare HamiltonTerminated
-
Azienda Ospedaliero-Universitaria di ParmaRegione Emilia-RomagnaCompletedGastric Cancer | Pancreatic Cancer | Non-small Cell Lung Cancer | Biliary Tract Cancer
-
University Hospital, GenevaSwiss National Science FoundationCompleted
-
Arcispedale Santa Maria Nuova-IRCCSUnknown
-
Seoul National University HospitalNational Cancer Center, Korea; Chonbuk National University Hospital; Asan Medical... and other collaboratorsCompletedStage IV Lung Cancer | Stage IV Pancreatic Cancer | Stage IV Breast Cancer | Pediatric Brain Tumor | Stage IV Colon Cancer | Stage IV Gastric Cancer | Stage IV Liver Cancer | Malignant Hematologic Neoplasm | Pediatric Solid Tumor | Pediatric Lymphoma | Biliary Cancer Metastatic | Pediatric LeukemiaKorea, Republic of
-
Alberta Health Services, CalgaryAlberta Cancer Foundation; University of VictoriaRecruitingLymphoma | Leukemia | Multiple Myeloma | Blood Cancer | Stem Cell Transplant Complications | Chimeric Antigen Receptor T-cell TherapyCanada